Thomas Synnott

As biologics, cell & gene therapies, radiopharmaceuticals, and other temperature-sensitive modalities scale, cold chain has become one of the most critical (and fragile) components of pharma logistics. This panel brings together leading manufacturers and logistics partners to discuss how they’re designing more resilient systems, strengthening monitoring and control, and adapting to new therapy requirements across the global network. Speakers will share strategies for ensuring product integrity, expanding cryogenic capability, enabling faster decision-making, and preparing the cold chain for the next decade of innovation.

• Strengthen end-to-end visibility and exception management to prevent temperature excursions and protect high-value assets
• Adapt cold chain designs to accommodate emerging modalities, from CAR-T to radiopharma to personalized therapies
• Increase agility through smarter packaging, lane strategy optimization, and tighter collaboration with partners